RecruitingPhase 3NCT06383780

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

A Randomized, Controlled, Multicenter Clinical Study Comparing the Efficacy of Pembrolizumab in Combination With Nab-TPC Regimen Versus the GP Regimen in the First-Line Treatment of Nasopharyngeal Carcinoma With Bone Metastases.

Sponsor

XIANG YANQUN

Enrollment

90 participants

Start Date

May 15, 2024

Study Type

INTERVENTIONAL

Conditions

Nasopharyngeal Carcinoma

Summary

This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of the immunotherapy drug tislelizumab with chemotherapy (GP or TPC regimens) to treat nasopharyngeal carcinoma (a type of throat cancer) that has spread to the bones. **You may be eligible if...** - You are 18 or older - You have nasopharyngeal carcinoma confirmed by biopsy that has spread to the bones - You have not previously received systemic (whole-body) therapy for your advanced cancer - You are in generally good health and your organs are functioning well **You may NOT be eligible if...** - You have only a small number of isolated bone spots (oligometastatic disease) - You have untreated spinal cord compression - You have a history of autoimmune disease - You have active infections including HIV, hepatitis B, or active tuberculosis - You are pregnant or breastfeeding - You have had severe heart problems within 3 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.